builderall

CONFERENCE INFORMATION

CONFERENCE DESCRIPTION

The Medical Educator Consortium is prepared to offer the 26th ADVANCES IN ONCOLOGY (AIO) to be held in person on October 31 and November 1, 2025. Course directors, Dr. Helen Chew and Dr. Primo Lara from UC Davis Comprehensive Cancer Center and The Medical Educator Consortium (Accreditor) have developed a multidisciplinary program which will bring together academic and community oncologists, nurses and pharmacists for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies.  It will include recent advances and new diagnostic and treatment modalities in hematologic, breast, lung, gastrointestinal, and genitourinary cancers. 

As a result of prior course participant evaluations and needs assessment surveys, the need for cutting edge information on prognostic markers and appropriate application of novel therapies has been identified. This year’s conference will specifically address these needs in the common malignancies identified by past participants as essential to their practice, including solid and hematologic cancers. The timing of this meeting in the fall allows for the latest findings in clinical cancer research from major hematology and oncology conferences to be presented and discussed. This educational activity also meets a unique need for the Northern California Sacramento Valley to provide a group of networked and collaborating oncologists a forum to discuss the most recent developments in oncology care in the context of local treatment approaches, patient populations, and open clinical trials. 

TARGET AUDIENCE

This conference is designed for physicians, nurses, and cancer health care providers, including medical, surgical and radiation oncologists, physician associates, pharmacists and other interested health care professionals. The conference includes didactic sessions from national oncology leaders and case-based panel discussions involving academic and community oncologists.

LEARNER OBJECTIVES

  • Identify advances in prognostic and predictive biomarkers and potential applications in therapeutic decision-making.

  • Integrate targeted and traditional therapeutic modalities in the treatment of cancer.

  • Assess newly validated treatment options for patients with solid tumors or hematologic malignancies

  • Apply data from recent clinical trials to determine the optimal course of therapy in defined patient populations, with emphasis on novel agents including mTOR inhibitors, ALK inhibitors, monoclonal antibodies, multi-targeted tyrosine kinase inhibitors, and inhibitors of cyclin kinase 4 and 6, among others.